Kybella dissolves fat. Morpheus8 works on skin. Kybella is deoxycholic acid, a bile acid injected into the fat pad under the chin, where it breaks open fat cells. Morpheus8 is radiofrequency microneedling - needles that place heat inside the dermis so collagen remodels.
The regulatory contrast is genuinely useful, and it runs the opposite way to most people's expectation. Kybella is a drug, approved under NDA 206333 on 29 April 2015 for "improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults." A drug approval requires adequate and well-controlled trials showing the product works for that specific use. Morpheus8 is a device, cleared through 510(k), a route that mainly requires showing the device is much like one already on the market - and its clearances name no cosmetic use at all: electrocoagulation and hemostasis, surgical wording for sealing tissue and stopping bleeding (K192695, 2019), then coagulation or contraction of soft tissue (K231790, 2023).
So the treatment that cleared the higher bar is approved for exactly the thing the other one is informally sold for. Double chins.
And Morpheus8 does not reduce fat. The one study that measured it took ultrasound scans under the chin in a split-face trial with 30 people completing, and found the dermis thickened while the fat layer did not change significantly. The paper is titled "...without Lipolysis."
Approved under NDA 206333 on 29 April 2015. There is no device clearance and no 510(k), because it is not a device.
Cleared through 510(k) under product code GEI, the FDA's category for electrosurgical cutting and coagulation devices.
The debris is then cleared by the immune system. The drug is not selective for fat cells, which is why injection technique and anatomy matter so much - misplaced, it will damage skin, muscle or nerve.
The label's Limitations of Use say the safe and effective use of Kybella for fat outside the submental region "has not been established and is not recommended."
The best-evidenced use of this device class is atrophic acne scars. There is no dedicated trial of radiofrequency microneedling for submental fat.
That is the whole approved indication, word for word.
No Morpheus8 clearance names wrinkles, laxity, acne scars, a double chin or any cosmetic use. Above 62 millijoules per pin, the clearance limits use to skin types I to IV.
The conventional description is roughly one to two weeks, though that duration is not a figure taken from the label. Of the two, this is the one with visible, socially awkward recovery.
Barrier function, measured as water loss through the skin, peaks on days one to three and is back to baseline by day seven.
The labelled risks that matter are injury to the marginal mandibular nerve, which causes an uneven smile, and difficulty swallowing.
No study has measured pain for facial radiofrequency microneedling against Kybella, so no comparison is offered. The one published pain figure in this literature comes from a very different setting - abdominal stretch marks with non-insulated needles, where radiofrequency microneedling scored 5.35 out of 10 against 2.35 for fractional CO2 - and it should not be read across to a facial treatment.
Most treatments on this site have little or no visible recovery. Kybella is the exception. Marked swelling, bruising, pain, numbness and firmness under the chin follow each session, and people generally plan around them. The conventional description is roughly one to two weeks; that is clinical convention rather than a figure quoted from the label.
Two labelled risks are worth knowing before you consent. The first is injury to the marginal mandibular nerve, which causes an uneven smile. The second is difficulty swallowing. There is no boxed warning on the label. The drug is not selective for fat cells, so where it goes matters - which is the argument for having it injected by someone who does it often and maps the anatomy first.
There is no dedicated trial of radiofrequency microneedling for submental fat. The one study that measured the fat layer found it unchanged while the dermis thickened.
What does appear in the record is unwanted fat loss. Fat loss is the third most-reported complication category in the FDA's post-market database for radiofrequency microneedling: 26 of 224 reported events between January 2013 and October 2025. MAUDE is a voluntary reporting system with no denominator, so that is a proportion of reports and not a chance that it happens to a patient. No incidence rate has been published, no case series describes it, and there is no established treatment for it.
The awkward part is that the mechanism marketing invokes to sell Morpheus8 for a double chin is the same one that shows up in the complaint data.
A PubMed search for Morpheus8 returns 16 records, and no randomised controlled trial was found. The research behind this device class comes from other machines - Lutronic Genius and Infini, Jeisys, Pollogen, Lumenis and several unnamed devices. The class evidence is real; it is simply not this brand's evidence.
Kybella destroys fat cells directly, and the label's expectation is a course of up to six sessions rather than a single fix. There is no published durability figure for it, so none is quoted.
For radiofrequency microneedling, the longest properly measured follow-up in the literature is six months. The clinic claim of one to three years has no published source. Collagen remodelling is measurable on biopsy by around four months, clinically meaningful change is generally not significant at one month, is significant at three, and holds at six. Beyond that there is no controlled data - and ageing carries on regardless of what either treatment did.
If you get cold sores, tell your provider when you book, not on the day. Antiviral medicine is started in advance, so it has to be prescribed beforehand. There is no published data on cold sore reactivation after radiofrequency microneedling specifically; the practice is carried over from laser resurfacing, where reactivation is well documented and prophylaxis is standard.
Before radiofrequency treatment, also disclose a pacemaker or an implantable defibrillator, and any metal implant near the treatment area. These are labelled contraindications for radiofrequency devices generally, and they are precautionary rather than tested - the right people to advise you are your cardiology team.